Press Release
- High quarterly profitability: Q1 FY27 EBITDA margin achieved 30.93% with consolidated PAT rising 32.13% YoY to ₹7.49 Cr.
- Funded capacity expansion: Deploying ₹132.62 Cr fresh IPO equity proceeds to double existing manufacturing capacity without adding balance sheet debt.
- Strategic diversification into defence: Executing a milestone purchase order for domestic private defence OEM platforms, potentially offering superior margin stability.
- Top-line growth stagnation: Q1 FY27 consolidated revenue grew just 2.68% YoY to ₹34.11 Cr, indicating core volume traction is currently sluggish.
- Execution and gestation lag: Doubling capacity requires 24-36 months for construction, machine installation, and OEM validation before contributing meaningfully to sales.
- Severe data opacity: Only 1 quarter of financials available post-listing (September 30, 2026); long-term ROCE, cash conversion, and balance sheet leverage cannot be verified.
- Standalone vs consolidated divergence: Standalone filings reveal Q1 revenue contraction (₹8.51 Cr vs ₹11.20 Cr), indicating subsidiaries drive the bulk of operating variance.
1. Ramp-Aware Impact & Financial Math
Current Baseline (Q1 FY27 Consolidated): - Revenue: ₹34.114 Cr (annualised run-rate: ~₹136.46 Cr) - Operating Profit (EBITDA): ₹10.551 Cr (30.93% margin) - PAT: ₹7.489 Cr (21.95% margin) - EPS: ₹2.15 (Implied post-IPO shares: ~3.48 Cr shares; Market Cap @ ₹193.30 = ~₹673 Cr) - Annualised EPS: ~₹8.60 (P/E ~22.5x)
Capex Ramp-Up Analysis: - Capex Announcement: Deploying ₹132.62 Cr of fresh IPO proceeds to double manufacturing capacity. - Relative Magnitude: Capex is ~0.97x annualised revenue. - Implementation Horizon: 2 to 3 years (FY27 to FY29) typically required for plant construction, machinery import, clean-room/tooling setup, and OEM component PPAP approvals. - Year 1 Impact (FY27): Very limited new capacity online. Revenue growth will rely primarily on existing facility debottlenecking and defense order execution (+10-15%). Projected Year 1 Revenue: ~₹150-155 Cr. PAT: ~₹32-34 Cr. - Steady-State Impact (FY29-FY30): Full doubling of capacity at 80-85% peak utilization translates to an incremental ~₹115-120 Cr in revenue, reaching ~₹250-260 Cr total revenue (+85-90% uplift). - Operating Leverage & Margins: Assuming blended EBITDA margins normalize slightly to 26-28% due to incremental depreciation and initial ramp overheads, steady-state PAT could reach ~₹50-52 Cr, representing an EPS of ~₹14.40 (+67% EPS uplift over current annualised base).
2. Industry Context & Capital Intensity
- Sector: Auto Parts / Machined Components / Defense OEM.
- Capital Intensity: Medium to High. Fixed assets turn around 1.0x - 1.5x for precision engineering.
- Industry Growth (CAGR): The domestic automotive component and defense localization space is projected to grow at 10-12% CAGR.
- Execution Difficulty: Medium. Automotive OEMs and defense platforms have lengthy qualification and testing cycles. Volume absorption is never immediate.
3. Multibagger Quality Checklist
- EPS Acceleration: PAT grew 32.13% YoY in Q1 FY27, though driven largely by margin expansion (+201 bps) rather than volume (+2.68% revenue growth).
- Revenue Momentum: Poor near-term momentum (+2.68% YoY), a significant red flag for a high-growth thesis.
- Margins: Exceptional EBITDA margin of 30.93%, but sustainability across high-volume automotive contracts remains unproven.
- Balance Sheet/ROCE: While unverified over a multi-year cycle, net debt should be contained post ₹132.6 Cr primary equity infusion.
- Catalyst Freshness: The deployment of ₹132.62 Cr IPO proceeds to double capacity is old news, having been the core thesis stated in the IPO prospectus ahead of the September 30, 2026 listing.
4. Valuation Scenarios (24-36 Months Horizon)
- Bull Case (80% Upside to ₹348): Flawless capex ramp by FY29, defense OEM orders surge to 30% of sales, sustaining 28%+ EBITDA margins. FY29 EPS reaches ₹16.00 at an exit multiple of 22x.
- Base Case (35% Upside to ₹260): Steady capex completion over 30 months; auto cycles cause minor utilization delays; revenue reaches ~₹220 Cr with normalized PAT of ~₹42 Cr (EPS ~₹12.00). Market re-rates to 21-22x trailing earnings.
- Bear Case (-35% Downside to ₹125): Core revenue continues to stagnate (<5% growth), defense orders face certification delays, and depreciation drag from new plant compresses margins down to 18-20%. Annualized EPS drops to ~₹6.50 at a derated multiple of 19x.
5. Verdict Rationale
Adroit Industries carries intriguing niche attributes (30%+ EBITDA margin, defense orders, zero-debt expansion via IPO equity), but the headline capex was already priced in via the recent listing, revenue growth in Q1 was stagnant at 2.68%, and historical verifiable data is limited to a single quarter. It qualifies as a POSSIBLE candidate rather than a STRONG_CANDIDATE until top-line reacceleration and capex commercialization are proven.